Goal to serve NewYork-Presbyterian’s providers and patients in the greater New York region and beyond.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and NewYork-Presbyterian, one of the nation’s largest and most comprehensive academic medical centers, today announced a strategic agreement designed to broaden access to quality, innovative laboratory services for the providers and patients of NewYork-Presbyterian, primarily in New York as well as the Tri-State area and beyond.

Under a definitive agreement, Quest will acquire select assets of the laboratory services business of NewYork-Presbyterian. NewYork-Presbyterian will still own and operate world-renowned hospital labs, including its anatomic pathology services, to continue providing high quality, complex clinical laboratory services with its academic partners.

“NewYork-Presbyterian and Quest share a belief that exceptional patient care should be accessible to all,” said Steven J. Corwin, MD, President and CEO of NewYork-Presbyterian. “We determined that working with Quest would be the best path – allowing our patients wider access to advanced, quality laboratory services.”

“NewYork-Presbyterian and Quest share much in common, including a keen focus on the patient, deep roots in New York and reputations nationwide and beyond for outstanding healthcare services,” said James E. Davis, CEO and President, Quest Diagnostics. “We also both recognize the foundational role of laboratory medicine to healthcare. Our agreement with NewYork-Presbyterian is designed to leverage Quest’s ability to deliver clinical laboratory services with outstanding innovation and quality.”

The parties expect to complete the transaction in the second quarter of 2023, pending customary regulatory approvals. Financial details of the transaction were not disclosed.